Fexapotide triflutate FDA Approval Status
FDA Approved: No
Generic name: fexapotide triflutate
Previous Name: NX-1207
Company: Nymox Pharmaceutical Corporation
Treatment for: Benign Prostatic Hyperplasia
Fexapotide triflutate is an injectable pro-apoptotic agent in development for the treatment of benign prostatic hyperplasia.
Development timeline for fexapotide triflutate
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.